Prior DNA microarray studies suggested that IL-16 mRNA levels decrease following T cell activation, a property unique among cytokines. We examined pro-IL-16 mRNA and protein expression in resting and anti-CD3 mAb-activated primary murine CD4 ؉ T cells. Consistent with the microarray reports, pro-IL-16 mRNA levels fell within 4 h of activation, and this response is inhibited by cyclosporin A. Total cellular pro-IL-16 protein also fell, reaching a nadir at 48 h. Pro-IL-16 comprises a C-terminal cytokine domain and an N-terminal prodomain that are cleaved by caspase-3. Pro-IL-16 expressed in transfected tumor cells was previously shown to translocate to the nucleus and to promote G 0 /G 1 arrest by stabilizing the cyclin-dependent kinase inhibitor p27
T he cytokine IL-16 was originally identified as a chemoattractant activity for CD4
ϩ T cells (1, 2) . Subsequent molecular cloning of the human and murine cDNA and genes revealed that the cytokine comprises the C-terminal end of a precursor molecule that is constitutively expressed in a high proportion of human peripheral blood T lymphocytes (3, 4) . Caspase-3 was identified as the protease responsible for cleaving pro-IL-16 (5); this is reminiscent of pro-IL-1␤ and pro-IL-18 cleavage by caspase-1, although these cytokines bear no sequence homology or known functional relationship to IL-16 (6) . Several biological activities in addition to chemoattractant activity have been attributed to IL-16, which appears to use CD4 as a receptor on target cells (7) .
The IL-16 prodomain is highly conserved across mammalian species and contains several modular functional sequences, including two PDZ domains and a CcN motif consisting of a nuclear localization signal (NLS), 3 and substrate sites for casein kinase (CK2) kinase and cdc2 kinase (3, 8) . These features suggest the potential for independent intracellular biological activities of the IL-16 prodomain, and this has been borne out by recent studies. Nuclear translocation of the IL-16 prodomain dependent on the NLS has been demonstrated in transfected COS cells (9) , and nuclear pro-IL-16 was reported to induce p27
Kip1 -dependent G 0 /G 1 arrest in transfected Jurkat cells by inhibiting transcription of Sphase kinase-associated protein (Skp2), which is a component of the ubiquitination complex that degrades p27
Kip1 (10) . These data suggest that pro-IL-16 may be involved in regulating T lymphocyte proliferation, given the abundant evidence that p27
Kip1 degradation is required for resting T cells to re-enter the cell cycle upon activation (11) (12) (13) .
In two DNA microarray studies reported by other laboratories, IL-16 mRNA levels in human T cells were shown to fall after activation with PMA plus ionomycin, anti-CD3 mAb plus PMA, or anti-CD3 plus anti-CD28 plus PMA (14, 15) . A third microarray study using tumor Ag-specific murine T cells also identified IL-16 among genes whose expression is down-modulated following activation (16) . These findings, together with the evidence that pro-IL-16 expression stabilizes p27
Kip1 , led to the proposal that activation-induced down-modulation of pro-IL-16 in T lymphocytes could be a necessary step to allow their subsequent proliferation (10) . To address this question, we studied the regulation of IL-16 mRNA and protein in primary murine CD4 ϩ T cells activated by anti-CD3 mAb. Our results confirm the activation-induced reduction of IL-16 mRNA and demonstrate a parallel decrease in intracellular pro-IL-16 protein. However, comparing wild-type and IL-16-deficient T cells, we found no difference in p27
Kip1 protein levels under basal or activated conditions and only subtle differences in assays of cell proliferation. We conclude that the absence of basal expression of pro-IL-16 is not sufficient to alter the proliferation of naive murine CD4 ϩ T cells. The dynamic regulation of pro-IL-16 mRNA and protein expression in activated T cells suggest functionally significant roles in this setting that remain to be discovered.
Materials and Methods

Antibodies
Polyclonal rabbit anti-mouse IL-16 prodomain Ab was generated by immunizing rabbits with a recombinant prodomain protein expressed in Escherichia coli (Strategic Biosolutions). Immune rabbit serum purified by protein A binding was validated by ELISA and Western blot. Unconjugated anti-mouse CD3 and anti-mouse CD28 mAb, as well as anti-human IL-16-PE (14.1), anti-mouse CD71 FITC (C2), anti-mouse CD4 PE (GK1.5), anti-BrdU FITC (3D4), and matching isotype controls were purchased from BD Pharmingen. Anti-␤-actin was purchased from Sigma-Aldrich.
Rabbit polyclonal anti-p27
Kip1 was purchased from Abcam.
Mice
Wild-type BALB/c mice were purchased from Taconic Farms and maintained in the Animal Medicine facility at University of Massachusetts Medical School. The Institutional Animal Care and Use Committee approved all experiments. IL-16-deficient mice were created by targeted mutation of the coding sequences for the mature IL-16 cytokine, leaving the prodomain intact. This was achieved by replacing all of exon VI and portions of exons V and VII with a neomycin resistance gene in reverse orientation. The mutated IL-16 gene fragment was ligated into pKO (Stratagene). After homologous recombination, this vector contained coding sequences for the IL-16 prodomain plus 18 residues of the IL-16 cytokine downstream from the caspase-3 site. The targeting construct was transfected into 129/SvJ embryonic stem cells, and 192 G418-resistant clones were isolated. Southern analysis with 5Ј-specific and 3Ј-specific probes and with a neo probe identified 10 candidates, one of which was injected into C57BL/6 embryoblasts that were implanted into pseudopregnant BALB/c females. From these procedures and subsequent breeding, homozygous IL-16 Ϫ/Ϫ mice were produced. Targeted disruption was confirmed by Southern analysis of genomic DNA and Northern analysis (data not shown), as well as by Western blot analysis for IL-16 protein in splenocytes using mAb 14.1 (see Fig.  5A ). Although mRNA sequences coding for the prodomain are expressed in these mice, the mutated pro-IL-16 protein appears to be unstable because it was not detectable by Western blot of splenocyte lysates using the polyclonal anti-prodomain Ab (see Fig. 4B ). Mice were backcrossed on the BALB/c or the C57BL/6 backgrounds for nine generations. Comparative studies were performed using IL-16 ϩ/ϩ littermate controls.
CD4 ϩ T cell isolation and activation
Pooled splenic and lymph node leukocytes were purified by density gradient centrifugation with Lympholyte-M (Cedarlane Laboratories), followed by positive selection using anti-CD4-conjugated magnetic beads (Dynal Biotech). By flow cytometry, the purified population contained Ͼ90% CD4 ϩ CD3 ϩ T cells. All cell cultures used RPMI 1640 medium (Invitrogen Life Technologies) supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, and 10 mM 2-ME. For activation, 24-well plates were coated with 2 g/ml anti-mouse CD3 mAb in HBSS (Invitrogen Life Technologies) at 4°C overnight. Three million CD4
ϩ T cells were added to each well and incubated at 37°C for various times, as indicated in Results.
Immunoblotting
Total cell lysates were prepared from activated CD4 ϩ T cells washed in cold PBS by incubation in radioimmunoprecipitation buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.25% Na-deoxycholate, and 1 mM PMSF on ice for 30 min, followed by centrifugation (14,000 ϫ g, 10 min). Supernatant protein concentration was measured by Bradford assay. Proteins (50 g per lane) were resolved by 10% SDS-PAGE, and then transferred to polyvinylidene difluoride membranes (Bio-Rad). Blots were blocked for 1 h with 5% nonfat dry milk in PBS, incubated with the primary Ab at room temperature for 2 h, and then washed three times with 0.05% Tween 20 in PBS. Blots were next incubated with HRP-labeled secondary Ab (Pierce) for 1 h at room temperature, and then washed three times with 0.05% Tween 20 in PBS. Immunoreactive bands were detected using SuperSignal West Pico Chemiluminescent Substrate (Pierce).
Real-time PCR analysis of IL-16, Skp2, and p27
Kip1 mRNA
Total RNA was extracted from CD4 ϩ T cells using TRIzol (Invitrogen Life Technologies) and treated with DNase I (30 min, 37°C). cDNA was prepared with the SuperScript First-Strand Synthesis System (Invitrogen Life Technologies) using 5 g of DNaseI-treated RNA and random hexamers. 
Proliferation assays
For in vitro proliferation, 1 ϫ 10 5 CD4 ϩ T cells/well were cultured in 96-well round-bottom plates in complete medium alone, or with the addition of anti-CD3 plus anti-CD28 mAb (1 g/ml each). At indicated intervals, cultures were pulsed with 0.4 Ci/well [ 3 H]thymidine for 18 h, harvested, and counted on a ␤ plate reader. All conditions were performed in quadruplicate. To assess the proliferative response of previously activated cells, CD4
ϩ T cells were first stimulated with anti-CD3 and anti-CD28 for 48 h. Cultures were then washed extensively, and cells were suspended in complete medium supplemented with 50 ng/ml rIL-2 expressed in our laboratory using Pichia pastoris. After 5 days, viable cells were recovered by density gradient centrifugation using Lympholyte-M and replated in equal numbers. Cells were then restimulated with anti-CD3 plus anti-CD28, and [ 3 H]thymidine incorporation was assessed 48 h later. For in vivo proliferation, mice were injected i.p. with 1 mg of BrdU (Sigma-Aldrich) four times over 48 h. Lymph nodes and spleens were harvested 12 h after the last injection.
Flow cytometry
Intracellular staining with PE-conjugated anti-human IL-16 mAb 14.1 was performed using Cytofix/Cytoperm kits (BD Pharmingen), according to the manufacturer's protocol. Cells were either unstimulated or treated with 2 g/ml Con A. Staining with mAb 14.1 was negative in IL-16 null mice, confirming the specificity of this mAb for detecting intracellular IL-16 in wild-type mice (data not shown). BrdU intracellular staining was done with a BrdU flow kit (BD Pharmingen), according to the manufacturer's protocol. Cells were stained with anti-BrdU FITC, mouse anti-CD4 PE, and 7-aminoactinomycin D. All counts were acquired using a BD LSR flow cytometer, and the data were analyzed using FlowJo software (TreeStar).
In other proliferation studies, splenocytes were stained in PBS containing 1 M CFSE (Molecular Probes) at 37°C for 15 min, and then pelleted and resuspended in complete medium for 30 min. Cells were next washed twice in PBS and then cultured in complete medium in the presence or absence of Con A (2 g/ml) for 48 or 72 h. Cells were harvested, stained with PerCP-labeled anti-CD4 mAb (BD Biosciences), and analyzed on a FACSCalibur flow cytometer (BD Biosciences). Analyses were performed on 2 ϫ 10 4 viable cells gated according to their forward/side scatter profile and CD4 expression. Data were analyzed using CellQuest software (BD Biosciences).
Results
IL-16 mRNA expression in resting and activated lymphocytes
IL-16 mRNA is constitutively expressed in mouse spleen, lymph nodes, and thymus (3). IL-16 mRNA is also constitutively expressed in human spleen, thymus, and PBMC (4). Despite its constitutive expression in a high proportion of naive lymphocytes, data from three independent DNA microarray studies suggest that IL-16 is dynamically regulated at the level of transcription (14 -16) . Using stimuli ranging from PMA plus ionophore to specific Ag, all three microarray studies identified IL-16 among genes whose expression was down-modulated after T cell activation. To confirm the microarray data, we measured IL-16 mRNA levels by real-time PCR in primary mouse CD4 ϩ T cells stimulated with plate-bound anti-CD3 mAb. Consistent with the microarray reports, we found that IL-16 mRNA is expressed in naive T cells and the level falls within 4 h of activation, partially recovering by 48 h (Fig. 1A) . Relative to ␤-actin, there was a maximal 5.3-fold reduction in the steady state IL-16 mRNA level 4 h after activation. Two of the previously cited DNA microarray studies also reported that down-modulation of IL-16 mRNA in human T cells activated with PMA plus ionophore or PMA plus anti-CD3 mAb was reversed by cyclosporin A (CsA) (14, 15) . To determine whether CsA similarly affects IL-16 expression in primary murine T cells, we treated purified CD4 ϩ T cells with 5 M CsA before anti-CD3 stimulation. In untreated T cells, we observed the expected activation-induced decline of IL-16 mRNA, whereas in cells pretreated with CsA there was a 2.4-fold increase in IL-16 expression relative to ␤-actin (Fig. 1B) . These data indicate that the downregulation of IL-16 mRNA expression occurring in activated T cells depends on the function of calcineurin and its downstream target NF-AT. A role for calcium signaling in the activation-dependent down-regulation of IL-16 was further supported by our observation that mRNA levels fall in CD4 ϩ T cells treated with ionomycin alone (Fig. 1C) .
IL-16 protein levels in resting and activated lymphocytes
A substantial proportion of circulating human T cells constitutively expresses pro-IL-16 protein. By flow cytometry with intracellular staining, over 70% of unstimulated human peripheral blood CD4
ϩ and CD8 ϩ T cells were found to be IL-16 positive (3). To characterize pro-IL-16 protein expression in primary murine T cells, we prepared lysates of unstimulated and anti-CD3-stimulated murine CD4 ϩ T cells for immunoblot analysis. Blots were probed with a rabbit polyclonal anti-mouse IL-16 prodomain Ab described in Materials and Methods. Consistent with the mRNA data, pro-IL-16 protein was readily detected in unstimulated cells, and the level dropped following activation ( Fig. 2A) . The pro-IL-16 protein level was moderately reduced by 4 h, reaching a nadir at 48 h after stimulation. Costimulation with anti-CD28 mAb did not amplify the pro-IL-16 response to stimulation using 1 g/ml anti-CD3, but anti-CD28 did increase the response to suboptimal concentrations of anti-CD3 (data not shown). Also consistent with the mRNA data, we found that CsA pretreatment preserved pro-IL-16 protein in anti-CD3-activated T cells, and pro-IL-16 protein levels declined in cells stimulated with ionomycin alone (Fig. 2B) .
The IL-16 protein content of resting and activated murine CD4 ϩ T cells was also examined by flow cytometry. The majority of naive CD4 ϩ T cells (74.6%) were IL-16 positive and CD71 negative. After stimulation with Con A, the majority population (78.9%) shifted to become IL-16 negative and CD71 positive (Fig.  3) . Although there was variability in the percentage of IL-16-positive CD4
ϩ T cells between experiments, a marked reduction from the basal level of IL-16 content was consistently seen after stimulation. Cells were prepared for intracellular staining using an antihuman IL-16 mAb (14.1) that recognizes an epitope in the C terminus of the pro-IL-16 cytokine domain (17) . A single amino acid ϩ T cells may be attributable to borderline sensitivity for murine IL-16 of the anti-human IL-16 mAb used for these experiments. In the immunoblot experiments, there was no significant variability of pro-IL-16 protein content in unstimulated T cells from different donors.
Influence of pro-IL-16 on cell cycle regulation
A major role for p27
Kip1 in the regulation of T cell proliferation has been confirmed by several laboratories. Hara et al. (18) reported that the degradation of p27
Kip1 following T cell activation is due initially to Skp2-independent ubiquitination, but that Skp2 mediates the persistent reduction of p27
Kip1 beyond 24 h. Huleatt et al. (13) found that p27
Kip1 levels drop in activated T cells, but are restored when activated cells are deprived of IL-2, coincident with cell cycle arrest. Together with evidence that pro-IL-16 stabilizes p27
Kip1 in Jurkat cells, these data suggested that the constitutive expression of pro-IL-16 might serve to block cycling of naive T cells. In this model, the down-regulation of pro-IL-16 that occurs after activation would permit entry of activated T cells into the cell cycle.
We created an IL-16 null mouse that lacks expression of fulllength pro-IL-16 protein, as described in Materials and Methods (Fig. 4) . Mice deficient in pro-IL-16 have no overt unstressed phenotype; they grow normally to adulthood and they have normal proportions of CD4 ϩ and CD8 ϩ T cells, although the yield of T cells from spleens of mature knockout mice is ϳ70% of the total for wild-type mice (our unpublished observations). To examine the effects of IL-16 deficiency on p27 Kip1 expression, we prepared immunoblots of lysates from naive and anti-CD3-activated wildtype and IL-16 null CD4 ϩ T cells (Fig. 5A ). There was no significant difference in the basal level of p27 Kip1 , nor in its activationinduced down-regulation. Withdrawal of IL-2 was previously reported to be a potent stimulus for the re-expression of p27
Kip1 in activated T cells (13) . When IL-16 null CD4 ϩ T cells were activated with anti-CD3 and then deprived of IL-2 by replacing the medium, p27
Kip1 increased comparably to the response of wildtype cells (Fig. 5B) . These results indicate that p27
Kip1 is not destabilized by the absence of pro-IL-16 in primary murine CD4 ϩ T cells.
The expression of IL-16, Skp2, and p27 Kip1 mRNA in naive and anti-CD3-activated wild-type and pro-IL-16 null CD4 ϩ T cells was measured by real-time RT-PCR (Fig. 6) . The primers used to amplify IL-16 are complementary to sequences retained in the mutated IL-16 gene. Normalized to ␤-actin, the basal expression of muted IL-16 sequence expressed in IL-16 null T cells was 4.2-fold higher compared with wild-type T cells, and dropped 3.8-fold after activation (data not shown). Consistent with the reported repressive effect of pro-IL-16 overexpression on Skp2 transcription in transfected Jurkat cells, the basal level of Skp2 mRNA was 4.3-fold increased in IL-16 null as compared with wild-type T cells (Fig. 6A) . Expression of Skp2 increased 9.1-fold after activation in IL-16 null T cells, and increased 5.8-fold in wild-type T cells.
Finally, there was no difference in basal p27
Kip1 mRNA expression comparing IL-16 null and wild-type T cells. Activation with anti-CD3 resulted in a 9-fold decrease of p27
Kip1 mRNA in wild-type T cells, and a 20.5-fold decrease in IL-16 null T cells (Fig. 6B) .
Together, these data demonstrate that the steady state level and activation-dependent increase in Skp2 mRNA expression are influenced by pro-IL-16, despite the lack of evidence for a dominant downstream effect on p27
Kip1 protein levels.
If pro-IL-16 functions to check the proliferation of naive T cells by a mechanism that lacks any redundant checkpoint controls, then it would be predicted that loss of pro-IL-16 should be sufficient to permit a hyperproliferative phenotype. This was first evaluated by comparing the CFSE dilution profile of IL-16 null and wild-type CD4 ϩ T cells following stimulation with anti-CD3 plus anti-CD28 for 48 or 72 h. Although some individual variation was observed, no consistent differences were seen in the profiles from IL-16 null or wild-type T cells (Fig. 7) . Proliferation of IL-16 null and wildtype CD4 ϩ T cells was also assessed by thymidine incorporation over 6 successive days following activation with anti-CD3 plus anti-CD28 mAb. IL-16 null T cells exhibited significantly higher thymidine incorporation than wild type on day 3, and there was a trend for greater incorporation by IL-16 null cells on day 2 that did not reach statistical significance (Fig. 8A) . However, there was no difference in thymidine incorporation between wild-type and IL-16 null T cells on days 4, 5, or 6, and no survival difference at any time point (Fig. 8B) . The proliferative response of previously activated CD4
ϩ T cells was tested by stimulation for 48 h with anti-CD3 plus anti-CD28, followed by incubation for 5 days in the (KO) CD4 ϩ T cells that were first activated with plate-bound anti-CD3 mAb for 48 h, then washed and incubated with fresh medium for 24 or 48 h to deplete IL-2. Lysates were analyzed for the presence of p27
Kip1 by immunoblotting with monoclonal anti-p27.
FIGURE 6. Skp2 and p27
Kip1 mRNA expression in IL-16 null and wildtype CD4 ϩ T cells. Total cellular RNA was harvested from unstimulated CD4 ϩ T cells (0 h) and cells stimulated with plate-bound anti-CD3 mAb for 4, 24, or 48 h for real-time RT-PCR measurement of Skp2 (A) and p27
Kip1 (B). The data are expressed as mean arbitrary units Ϯ SD (n ϭ 3), by normalization to ␤-actin at each time point. presence of rIL-2. Viable cells were recovered by density gradient centrifugation and replated in equal numbers for restimulation with anti-CD3 plus anti-CD28. Thymidine incorporation measured at 48 h was significantly lower in IL-16 null CD4
ϩ T cells as compared with wild type (Fig. 8C) . The basis for these subtle but reproducible and statistically significant differences in T cell proliferation remains to be determined, but the data do not support the hypothesis that any effect of pro-IL-16 on the cell cycle occurs via a nonredundant pathway.
To further test the hypothesis that pro-IL-16 expression is necessary to maintain resting T cells in a nonproliferating state, we conducted in vivo cell cycle analysis using BrdU incorporation. Cells from the spleen and lymph nodes were purified and analyzed separately by flow cytometry with intracellular staining for BrdU and surface staining for CD4. Comparing IL-16 null and wild-type cells, there were no statistically significant differences in the percentage of BrdU-positive, G 0 /G 1 , G 2 ϩ M, or S cells (Table I) . A limited comparison of BrdU incorporation of T cells harvested from draining lymph nodes 2 wk after s.c. injection of Mycobacterium bovis bacillus Calmette-Guerin also failed to identify any difference in the response of wild-type or IL-16 null T cells (data not shown).
Discussion
Pro-IL-16 mRNA and protein are constitutively expressed in a high proportion of T lymphocytes freshly isolated from peripheral blood, spleen, lymph node, and thymus. Several prior DNA microarray studies indicated that IL-16 is among the most strongly down-regulated mRNA species during T cell activation, and the only cytokine gene whose expression is not increased in this setting (14, 16, 19) . In the present study, we measured pro-IL-16 mRNA by real-time PCR in primary murine CD4 ϩ T cells before and after stimulation with plate-bound anti-CD3 mAb. Our results confirm the microarray data by demonstrating a Ͼ5-fold decline in IL-16 mRNA, and for the first time we show that pro-IL-16 protein levels in murine CD4 ϩ T cells also decrease in an activation-dependent manner. In addition, we confirmed that the down-regulation of pro-IL-16 mRNA is inhibited by CsA, indicating that IL-16 gene expression is modulated by a calcium signal following T cell activation. Additional evidence that calcium signaling plays a role in the activation-dependent regulation of pro-IL-16 was provided by experiments showing that pro-IL-16 mRNA and protein levels fall in response to ionomycin treatment.
Pro-IL-16 is a bifunctional molecule; cleavage by caspase-3 releases the IL-16 cytokine that is exported to the extracellular space by an unknown mechanism to act in trans on IL-16-responsive cells through its interaction with CD4 and possibly other surface receptors (7, 20, 21) . The remaining IL-16 prodomain contains PDZ domains and a CcN motif, suggesting functions involving protein-protein interactions and nuclear translocation. Indeed, Bannert et al. (22) identified myosin phosphatase-targeting subunits as PDZ-mediated binding partners of pro-IL-16 by yeast twohybrid screening. In independent two-hybrid studies, we observed a similar interaction with myosin phosphatase-targeting subunits, and we also identified the adaptor protein Lasp-1 as a pro-IL-16-binding partner (S. Kim, unpublished observations). Lasp-1 is comprised of a LIM domain, a Src homology 3 domain, and an actin binding domain (23) . These data suggest an association of pro-IL-16 or its prodomain with molecular complexes involving the cytoskeleton, but to date provide no further insight to its functions.
Building on the observation that expression of the IL-16 prodomain in tumor cell lines triggered growth arrest and apoptosis, Zhang et al. (9) have developed a solid body of evidence supporting a role for IL-16 in cell cycle regulation. In COS cells transfected with full-length pro-IL-16 constructs having N-terminal GFP and C-terminal FLAG fusions, they determined that fulllength pro-IL-16 localizes to perinuclear and reticular regions in the cell. COS cells constitutively express activated caspase-3 and spontaneously cleave the transfected pro-IL-16. By confocal microscopy, the cleaved IL-16 prodomain fragment was observed to target the nucleus, and this was abrogated by mutation of the NLS. Expression of the IL-16 prodomain in transfected COS cells was also shown to mediate G 0 /G 1 cell cycle arrest, and this activity was dependent on nuclear translocation. Subsequently, this group determined that nuclear translocation of the IL-16 prodomain is controlled by a phosphorylation-regulated CcN motif, and that mutation of either the CK2 substrate site or the cdc2 kinase impairs the ability of the IL-16 prodomain to induce G 0 /G 1 cell cycle arrest (8) . A mechanism for the influence of pro-IL-16 on T cell cycle was reported recently by Center et al. (10) . Using Jurkat cells stably transfected with inducible pro-IL-16 expression vectors, it was shown that ectopic expression of pro-IL-16 stabilizes the cyclin-dependent kinase inhibitor p27
Kip1 by repressing the transcription of Skp2, a critical component of the SCF Skp2 ubiquitin E3 ligase complex that degrades p27
Kip1 and was sufficient to induce cell cycle arrest at G 1 in pro-IL-16-negative Jurkat cells. Those studies did not address the question posed in this manuscript as to whether the loss of pro-IL-16 is necessary to permit entry of primary T cells into S phase following TCR activation and whether it is sufficient to permit normal resting T cells to proliferate without a stimulus. A critical role for pro-IL-16 in regulating T cell cycle was also suggested by the intriguing observation that pro-IL-16 is mutated in three additional T cell tumor lines (HUT78, SUP-T1, and H9). HUT78 and SUP-T1 lack nuclear expression of endogenous pro-IL-16 expression due to gene deletion. Pro-IL-16 is expressed in H9 cells, but in these cells NLS is mutated.
Based on the data from pro-IL-16-transfected cells, we anticipated that CD4 ϩ T cells from mice deficient in IL-16 would exhibit a hyperproliferative phenotype. Indeed, basal and stimulated levels of Skp2 mRNA are elevated in IL-16 null CD4 ϩ T cells consistent with the reported repression of Skp2 transcription by pro-IL-16 in transfected human cell lines. Despite the increase in Skp2 mRNA levels in IL-16 null mice, there is no corresponding reduction in p27
Kip1 protein and no alternation in the dynamic regulation of p27
Kip1 following T cell activation or IL-2 withdrawal. We found little evidence to suggest that T cells lacking pro-IL-16 are hyperproliferative. Following primary stimulation in vitro, IL-16 null T cells demonstrate a transient, but consistent increase in thymidine incorporation at 72 h. However, there is no consistent difference in CFSE dilution profiles, and there appears to be no net increase in proliferating cells or any difference in the survival of activated T cells. To circumvent the artificial conditions of in vitro T cell culture, we also analyzed the proliferation of T cells labeled in vivo with BrdU. These experiments failed to reveal any cell cycle differences in splenic or lymph node CD4 ϩ T cells from wild-type and IL-16 null mice. Although the data do not support a role for pro-IL-16 in holding naive cells in G 0 , the differences in Skp2 mRNA expression and thymidine incorporation by IL-16 null cells suggest that pro-IL-16 functions in some way to influence T cell cycling following TCR activation. The apparently normal expression of p27
Kip1 in IL-16 null T cells might reflect compensatory mechanisms established in development. Alternatively, our data could reflect a regulatory scheme in which the influence of endogenous pro-IL-16 and Skp2 on p27 Kip1 is not a dominant factor for primary murine CD4 ϩ T cells under the activation conditions that we studied. In this regard, degradation of p27
Kip1 at the G 0 -G 1 transition was reported to be mediated by Skp2-independent ubiquitination pathway (18) . Thus, while the ectopic expression of nuclear pro-IL-16 is sufficient to maintain G 1 in human T cell tumor lines, its absence is not sufficient to permit primary T cells to continuously cycle once activated.
Aside from the PDZ domains and other functional motifs shared with a wide range of genes, pro-IL-16 is a unique molecule with no apparent family members. The amino acid sequence of IL-16 is highly conserved across mammalian species, and this sequence conservation spans both cytokine domain and the prodomain of pro-IL-16 (3). These features suggest that IL-16 and the prodomain of its precursor protein serve important and potentially nonredundant functions in T cells. In the present study, we found that pro-IL-16 expression is dynamically regulated during CD4 ϩ T activation. Although pro-IL-16 does not appear to check the proliferation of naive T cells, our data suggest a role for pro-IL-16 in T cell activation and cell cycle events that has yet to be identified. Macian et al. (24) reported that NF-AT activation by ionomycin induces a limited set of anergy-associated genes in T cells, and a functional state of TCR unresponsiveness. Based on our finding that ionomycin induces pro-IL-16 mRNA and protein down-regulation, we are currently investigating a possible role for pro-IL-16 in tolerance.
